These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 23690293)

  • 1. Development of LC/MS/MS, high-throughput enzymatic and cellular assays for the characterization of compounds that inhibit kynurenine monooxygenase (KMO).
    Winkler D; Beconi M; Toledo-Sherman LM; Prime M; Ebneth A; Dominguez C; Muñoz-Sanjuan I
    J Biomol Screen; 2013 Sep; 18(8):879-89. PubMed ID: 23690293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington's disease.
    Toledo-Sherman LM; Prime ME; Mrzljak L; Beconi MG; Beresford A; Brookfield FA; Brown CJ; Cardaun I; Courtney SM; Dijkman U; Hamelin-Flegg E; Johnson PD; Kempf V; Lyons K; Matthews K; Mitchell WL; O'Connell C; Pena P; Powell K; Rassoulpour A; Reed L; Reindl W; Selvaratnam S; Friley WW; Weddell DA; Went NE; Wheelan P; Winkler C; Winkler D; Wityak J; Yarnold CJ; Yates D; Munoz-Sanjuan I; Dominguez C
    J Med Chem; 2015 Feb; 58(3):1159-83. PubMed ID: 25590515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lead discovery for human kynurenine 3-monooxygenase by high-throughput RapidFire mass spectrometry.
    Lowe DM; Gee M; Haslam C; Leavens B; Christodoulou E; Hissey P; Hardwicke P; Argyrou A; Webster SP; Mole DJ; Wilson K; Binnie M; Yard BA; Dean T; Liddle J; Uings I; Hutchinson JP
    J Biomol Screen; 2014 Apr; 19(4):508-15. PubMed ID: 24381207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Surface Plasmon Resonance Assay for the Characterization of Small-Molecule Binding Kinetics and Mechanism of Binding to Kynurenine 3-Monooxygenase.
    Poda SB; Kobayashi M; Nachane R; Menon V; Gandhi AS; Budac DP; Li G; Campbell BM; Tagmose L
    Assay Drug Dev Technol; 2015 Oct; 13(8):466-75. PubMed ID: 26292018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural basis of kynurenine 3-monooxygenase inhibition.
    Amaral M; Levy C; Heyes DJ; Lafite P; Outeiro TF; Giorgini F; Leys D; Scrutton NS
    Nature; 2013 Apr; 496(7445):382-5. PubMed ID: 23575632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kynurenine 3-monooxygenase from Pseudomonas fluorescens: substrate-like inhibitors both stimulate flavin reduction and stabilize the flavin-peroxo intermediate yet result in the production of hydrogen peroxide.
    Crozier-Reabe KR; Phillips RS; Moran GR
    Biochemistry; 2008 Nov; 47(47):12420-33. PubMed ID: 18954092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overexpression of human kynurenine-3-monooxygenase protects against 3-hydroxykynurenine-mediated apoptosis through bidirectional nonlinear feedback.
    Wilson K; Auer M; Binnie M; Zheng X; Pham NT; Iredale JP; Webster SP; Mole DJ
    Cell Death Dis; 2016 Apr; 7(4):e2197. PubMed ID: 27077813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kynurenine-3-monooxygenase: a review of structure, mechanism, and inhibitors.
    Smith JR; Jamie JF; Guillemin GJ
    Drug Discov Today; 2016 Feb; 21(2):315-24. PubMed ID: 26589832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kynurenine-3-monooxygenase (KMO): From its biological functions to therapeutic effect in diseases progression.
    Chen Y; Zhang J; Yang Y; Xiang K; Li H; Sun D; Chen L
    J Cell Physiol; 2022 Dec; 237(12):4339-4355. PubMed ID: 36088660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The novel KMO inhibitor CHDI-340246 leads to a restoration of electrophysiological alterations in mouse models of Huntington's disease.
    Beaumont V; Mrzljak L; Dijkman U; Freije R; Heins M; Rassoulpour A; Tombaugh G; Gelman S; Bradaia A; Steidl E; Gleyzes M; Heikkinen T; Lehtimäki K; Puoliväli J; Kontkanen O; Javier RM; Neagoe I; Deisemann H; Winkler D; Ebneth A; Khetarpal V; Toledo-Sherman L; Dominguez C; Park LC; Munoz-Sanjuan I
    Exp Neurol; 2016 Aug; 282():99-118. PubMed ID: 27163548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Substrate and inhibitor specificity of kynurenine monooxygenase from Cytophaga hutchinsonii.
    Phillips RS; Anderson AD; Gentry HG; Güner OF; Bowen JP
    Bioorg Med Chem Lett; 2017 Apr; 27(8):1705-1708. PubMed ID: 28302400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.
    Thevandavakkam MA; Schwarcz R; Muchowski PJ; Giorgini F
    CNS Neurol Disord Drug Targets; 2010 Dec; 9(6):791-800. PubMed ID: 20942784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Kynurenine Pathway and Kynurenine 3-Monooxygenase Inhibitors.
    Hughes TD; Güner OF; Iradukunda EC; Phillips RS; Bowen JP
    Molecules; 2022 Jan; 27(1):. PubMed ID: 35011505
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A magnetic bead-based ligand binding assay to facilitate human kynurenine 3-monooxygenase drug discovery.
    Wilson K; Mole DJ; Homer NZ; Iredale JP; Auer M; Webster SP
    J Biomol Screen; 2015 Feb; 20(2):292-8. PubMed ID: 25296660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted deletion of kynurenine 3-monooxygenase in mice: a new tool for studying kynurenine pathway metabolism in periphery and brain.
    Giorgini F; Huang SY; Sathyasaikumar KV; Notarangelo FM; Thomas MA; Tararina M; Wu HQ; Schwarcz R; Muchowski PJ
    J Biol Chem; 2013 Dec; 288(51):36554-66. PubMed ID: 24189070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kynurenine 3-Monooxygenase Activity in Human Primary Neurons and Effect on Cellular Bioenergetics Identifies New Neurotoxic Mechanisms.
    Castellano-Gonzalez G; Jacobs KR; Don E; Cole NJ; Adams S; Lim CK; Lovejoy DB; Guillemin GJ
    Neurotox Res; 2019 Apr; 35(3):530-541. PubMed ID: 30666558
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First molecular modeling report on novel arylpyrimidine kynurenine monooxygenase inhibitors through multi-QSAR analysis against Huntington's disease: A proposal to chemists!
    Amin SA; Adhikari N; Jha T; Gayen S
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5712-5718. PubMed ID: 27838184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual role of the carboxyl-terminal region of pig liver L-kynurenine 3-monooxygenase: mitochondrial-targeting signal and enzymatic activity.
    Hirai K; Kuroyanagi H; Tatebayashi Y; Hayashi Y; Hirabayashi-Takahashi K; Saito K; Haga S; Uemura T; Izumi S
    J Biochem; 2010 Dec; 148(6):639-50. PubMed ID: 20802227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kynurenine 3-monooxygenase is implicated in antidepressants-responsive depressive-like behaviors and monoaminergic dysfunctions.
    Tashiro T; Murakami Y; Mouri A; Imamura Y; Nabeshima T; Yamamoto Y; Saito K
    Behav Brain Res; 2017 Jan; 317():279-285. PubMed ID: 27693848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kynurenine 3-monooxygenase is a critical regulator of renal ischemia-reperfusion injury.
    Zheng X; Zhang A; Binnie M; McGuire K; Webster SP; Hughes J; Howie SEM; Mole DJ
    Exp Mol Med; 2019 Feb; 51(2):1-14. PubMed ID: 30760699
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.